RxDoctor Payments Data

Yesenia Keller, NP

Family · Chula Vista, CANPI 1851006514

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 30 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$217
  • Novartis$210
  • Medtronic$192
  • Lexicon Pharmaceuticals, Inc.$125
  • Boehringer Ingelheim$90
  • Amgen$85
  • plus $240 from 6 others

What the payments were for

  • Food & beverage$1,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,160 in reported general payments places this provider in the 75th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$10,056
Medicare patients
51
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin165$100,950
OzempicSemaglutide46$43,208
EliquisApixaban26$28,220
EntrestoSacubitril/Valsartan18$11,786
FarxigaDapagliflozin Propanediol18$11,741
TrulicityDulaglutide12$11,308
Repatha SureclickEvolocumab13$9,017
Atorvastatin Calcium71$989
Losartan Potassium45$334
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19$321
Rosuvastatin Calcium14$243
Olmesartan Medoxomil25$238
Amlodipine Besylate53$177
Isosorbide Mononitrate ErIsosorbide Mononitrate21$168
Metoprolol Succinate11$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$90$100,950165 claims
Novo NordiskOzempic$217$43,20846 claims
NovartisEntresto$210$11,78618 claims
AstraZenecaFarxiga$26$11,74118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,634 family providers in California.

Other family in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →